Skip to main contentAI and Advanced
/
BETA · NSEMarket ticker unavailable · configure an authorised index feed
BE
NSE · Equity shares · Biotechnology & Drugs-59.90 · -2.83%
Beta Drugs BETA
NSE:INR 2,059.1
BSE:Not available
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for BETA
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 2,119
Day rangeINR 2,002.6 — INR 2,094.7
52-week rangeINR 990.1 — INR 2,712
Volume13,984
Market cap2,362
P/E26.5
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)384.83
Net Income (INR Cr)41.48
Rev Growth (5 Year %)27.08
EPS Growth (5 Year %)28.64
P/E Ratio26.5
Book Value231.7
EPS40.92
Price/BV8.89Computed
Research path: Interpret Beta Drugs's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
BETABeta Drugs1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 495.8 | 436.23 | 254.1 |
| Cash Equivalents | 124.85 | Not available | Not available |
| Other Liabilities Total | 9.56 | 9.41 | 6.27 |
| Long Term Debt | 133.32 | 126.99 | 6.04 |
| Common Stock Total | 10.14 | 10.09 | 9.61 |
| Other Current Assets Total | 1.27 | 0 | 0 |
| Total Assets | 495.8 | 436.23 | 254.1 |
| Total Equity | 244.77 | 197.1 | 157.12 |
| Long Term Investments | 17.96 | Not available | 0 |
| Retained Earnings(Accumulated Deficit) | 234.63 | 163.53 | 123.56 |
| Total Common Shares Outstanding | 1.01 | 1.01 | 1.01 |
| Tangible Book Valueper Share Common Eq | 231.7 | 186.76 | 150.31 |
| Total Liabilities | 251.03 | 239.14 | 96.98 |
| Total Debt | 147.81 | 138.06 | 14.71 |
| Short Term Investments | 15.45 | 130.14 | 19.89 |
| Cashand Short Term Investments | 140.3 | 147.02 | 28.63 |
| Total Receivables Net | 119.13 | 117.88 | 92.32 |
| Notes Payable/Short Term Debt | 14.48 | 5.71 | 4.96 |
| Accounts Receivable-Trade Net | 119.13 | 103.08 | 79.24 |
| Property/Plant/Equipment Total-Net | 115.37 | 80.36 | 59.2 |
| Total Current Liabilities | 108.14 | 102.73 | 84.67 |
| Total Inventory | 74.46 | 65.16 | 56.39 |
| Accounts Payable | 80.63 | 71.25 | 59.27 |
| Other Currentliabilities Total | 13.03 | 20.42 | 16.73 |
| Total Long Term Debt | 133.32 | 126.99 | 6.04 |
| Intangibles Net | 9.9 | 5.83 | 2.64 |
| Other Long Term Assets Total | 17.42 | 2.08 | 1.47 |
| Total Current Assets | 335.16 | 331.08 | 177.87 |
| Accumulated Depreciation Total | Not available | -54.61 | -43.3 |
| Prepaid Expenses | Not available | 1.01 | 0.52 |
| Current Portof LT Debt/Capital Leases | Not available | 5.35 | 3.71 |
| Additional Paid-In Capital | Not available | 23.47 | 23.94 |
| Cash | Not available | 16.88 | 8.74 |
| Property/Plant/Equipment Total-Gross | Not available | 134.97 | 102.37 |
| Goodwill Net | Not available | 2.75 | 2.75 |
| Note Receivable-Long Term | Not available | 14.14 | 10.17 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio5.32
Price to Sale Ratio6.14
Growth
Debt 5Yr CAGR %53.29
Margins
Operating Margin 12m15.21
Operating Margin 5y Avg17.14
Net Profit Margin 12m10.78
Net Profit Margin 5y12.41
Yield
Dividend Yield %0
Risk and consensus
Source-qualified signals
Risk metrics
Risk metrics unavailable.
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,937.8 | 4.65 L | 38.4 | — |
| Divi's Laboratories | INR 7,377 | 1.96 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,982.05 | 1.69 L | 72.73 | — |
| Cipla | INR 1,408.5 | 1.14 L | 27.57 | — |
| Zydus Lifesciences | INR 1,118.05 | 1.11 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 59.10%
- FII
- 1.02%
- Other
- 39.88%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Beta Drugs Reports Q1 Consolidated Net Profit of 158M Rupees, Revenue at 1.27B Rupees - SahiMarket news · 21 Jul 2026, 9:37 am
Beta Drugs Reports Q1 Consolidated Net Profit of 158M Rupees, Revenue at 1.27B Rupees Sahi
Beta Drugs net profit rises 40.9% in Q1FY27 - scanx.tradeMarket news · 21 Jul 2026, 1:29 am
Beta Drugs net profit rises 40.9% in Q1FY27 scanx.trade
Beta Drugs Q1 FY27: Stellar 74.59% Profit Surge Defies Industry Headwinds - MarketsMojoMarket news · 20 Jul 2026, 8:01 pm
Beta Drugs Q1 FY27: Stellar 74.59% Profit Surge Defies Industry Headwinds MarketsMojo
Power Grid Corporation of India Ltd gains for third straight session - Business StandardMarket news · 20 Jul 2026, 1:31 pm
Power Grid Corporation of India Ltd gains for third straight session Business Standard
Beta Drugs Shares Soar 17% After Q1 PAT Jumps 41% and Margin Expansion - Trade BrainsMarket news · 20 Jul 2026, 11:15 am
Beta Drugs Shares Soar 17% After Q1 PAT Jumps 41% and Margin Expansion Trade Brains
Corporate actions
Events
- board MeetingsTo consider and approve the financial results for the period ended Jun 30, 2026
- board MeetingsAudited Results
- board MeetingsQuarterly Results
- board MeetingsTo consider 1. Approve the Employee Stock Option Plan (ESOP). 2. Acquisition of equity shares of a target company from certain shareholders of the target company. 3. Other business matters.
- board MeetingsQuarterly Results
- board MeetingsAudited Results
- board MeetingsTo consider other business matters :- The allotment of 4,80,693 fully paid-up equity shares of the Company of face value of INR 10 each, under Bonus Issue.
- bonusBonus issue of equity shares in the ratio of 1:20 of Rs. 10/-.
Rusaka Markets Community
Discussion and sentiment for Beta Drugs
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Beta Drugs Limited is an India-based oncology medicine manufacturing company. The Company specializes in the intricate field of complex chemical synthesis for anti-cancer bulk drugs and finished dosages. The Company operates through one segment, Pharmaceuticals. Its product category includes cosmeceutical products and oncology products. The cosmeceutical products include La’Thrix, BACINOX, URTICALM, HUMIDA, NUSPLASH, UVIREX, ADVIBE, SENSIBAR, and RECAPRO. The oncology products include Temozad(Temozolomide), ADVIN(Vinorelbine), ADSIDE(Etoposide), ADRIB(Doxorubicin), ADCOV(Leucovorin calcium), ADPLATIN(Oxaliplatin), INOTAD(Irinotecan), ADCIST(Cisplatin), ADCARB(Carboplatin), ERLOTAD(Erlotinib), ADOXI(Docetaxel), AMGICIN(Gemcitabine), ADPAXIL(Paclitaxel), ADMIDE(Bicalutamide), and others. The Company's subsidiaries include Adley Lab Limited and Adley Formulations Private Limited.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- BETA
Questions
Stock FAQ
What is the symbol and ISIN of Beta Drugs?
Beta Drugs has the symbol BETA and ISIN - INE351Y01019.
What is the current price of Beta Drugs?
Beta Drugs is currently trading at INR 2,059.10.
What are the year high and year low of Beta Drugs?
Beta Drugs has a year high of INR 2,712.00 and a year low of INR 990.10.
What is the market capitalization of Beta Drugs?
Beta Drugs has a market capitalization of INR 2,362.00 crore.
What is the P/E ratio of Beta Drugs?
Beta Drugs has a P/E ratio of 26.50.
What is the dividend yield of Beta Drugs?
Beta Drugs has a dividend yield of 0.00%.
How is the financial performance of Beta Drugs based on revenue, net income, and EPS?
Beta Drugs has revenue of INR 384.83 crore, net income of INR 41.48 crore, and EPS of INR 44.88.
What is the book value of Beta Drugs?
Beta Drugs has a book value of INR 231.70.
What is the debt-to-equity ratio of Beta Drugs?
Beta Drugs has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Beta Drugs?
Beta Drugs has a price-to-book ratio of 8.89 and a price-to-sales ratio of 6.14.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.